Huge pharmaceutical deal: Platinum Equity gains control of Inventia Healthcare’s key division
In a significant move within the global pharmaceutical sector, Platinum Equity has secured a controlling stake in the Oral Solid Dosage (OSD) business of Inventia ... Read More
Nestlé Health Science to acquire VOWST assets from Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced a significant development in its partnership with Nestlé Health Science—a non-binding memorandum of understanding whereby Nestlé Health Science ... Read More
Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 ... Read More
Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental ... Read More
Takeda’s $62bn acquisition of Shire: A game-changing move for global pharma
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for ... Read More
Lilly to acquire Loxo Oncology in $8bn deal: A game-changer in precision cancer treatment
Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More
Brooklyn Immuno Therapeutics acquires IRX Therapeutics’ assets for cytokine-based cancer therapy
Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics' assets. The terms of ... Read More
Cambrex set to acquire Halo Pharma for $425m to expand into finished dosage form market
In a significant expansion of its capabilities, Cambrex Corporation has announced its agreement to acquire Halo Pharma, a US-based contract development and manufacturing organization (CDMO), ... Read More